After obtaining his Masters degree in Pharmaceutical Sciences, Philip pursued his research interest as a graduate student at the Amsterdam University Medical Center. Under the mentorship of Prof. Rogier Sanders, as well as Dr. Neil King at the University of Washington, he worked on the development of two-component protein nanoparticle vaccines. His graduate work has yielded promising vaccine strategies for HIV-1, SARS-CoV-2 and Lassa virus and has led to him receiving his Ph.D. in 2021. With the support of a Rubicon Fellowship from the Netherlands Scientific Organization, Philip is currently performing postdoctoral research in the lab of Prof. Andrew Ward at the Scripps Research Institute. Here he is using electron microscopy techniques to map Lassa virus-specific antibody responses induced by infection or vaccination.